Tarik Asselah1, Hendrik Reesink2, Jan Gerstoft3, Victor de Ledinghen4, Paul J Pockros5, Michael Robertson6, Peggy Hwang6, Ernest Asante-Appiah6, Janice Wahl6, Bach-Yen Nguyen6, Eliav Barr6, Rohit Talwani6, Lawrence Serfaty7. 1. Hepatology Department, AP-HP, University Paris Diderot, INSERM UMR1149, Beaujon Hospital, Clichy, France. 2. Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands. 3. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. 4. Service d'Hépato-Gastroentérologie, Hôpital Haut-Lévêque, CHU Bordeaux, Pessac, France. 5. Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA, USA. 6. Merck & Co., Inc., Kenilworth, NJ, USA. 7. Department of Hepatology, Saint-Antoine Hospital, Paris, France.
Abstract
BACKGROUND & AIMS: The aim of this integrated analysis was to assess the efficacy of the once-daily combination of elbasvir 50 mg and grazoprevir 100 mg, with and without ribavirin in HCV genotype 4 (GT4)-infected participants enrolled in the Phase 2/3 clinical programme with elbasvir/grazoprevir. METHODS: Treatment-naïve and treatment-experienced participants 18 years of age or older with chronic HCV GT4 infection and baseline HCV RNA ≥10 000 IU/mL were included in the analysis. The analysis population was the full analysis set (FAS; all participants who received at least 1 dose of study medication) and a total of 155 HCV GT4 participants were evaluated. The primary endpoint was sustained virologic response at week 12 (SVR12; HCV RNA less than the lower limit of quantitation at 12 weeks after the completion of study therapy). RESULTS: Overall, among GT4-infected participants treated with 12 or 16 weeks of elbasvir/grazoprevir ± ribavirin, the SVR12 efficacy rates were 96.4% (107/111) in treatment-naïve participants and 88.6% (39/44) in treatment-experienced participants. The SVR12 rates were 96.0% (97/101) in treatment-naïve participants treated with 12 weeks of elbasvir/grazoprevir and 100% (8/8) in treatment-experienced participants treated with 16 weeks of elbasvir/grazoprevir plus ribavirin. Efficacy was not impacted by GT4 subtype. CONCLUSIONS: The regimens of 12 weeks of elbasvir/grazoprevir without ribavirin, and 16 weeks of elbasvir/grazoprevir plus ribavirin, were efficacious in HCV GT4-infected treatment-naïve and treatment-experienced participants respectively. Baseline NS5A resistance-associated substitutions did not impact the efficacy of elbasvir/grazoprevir in GT4-infected participants.
BACKGROUND & AIMS: The aim of this integrated analysis was to assess the efficacy of the once-daily combination of elbasvir 50 mg and grazoprevir 100 mg, with and without ribavirin in HCV genotype 4 (GT4)-infected participants enrolled in the Phase 2/3 clinical programme with elbasvir/grazoprevir. METHODS: Treatment-naïve and treatment-experienced participants 18 years of age or older with chronic HCV GT4 infection and baseline HCV RNA ≥10 000 IU/mL were included in the analysis. The analysis population was the full analysis set (FAS; all participants who received at least 1 dose of study medication) and a total of 155 HCV GT4 participants were evaluated. The primary endpoint was sustained virologic response at week 12 (SVR12; HCV RNA less than the lower limit of quantitation at 12 weeks after the completion of study therapy). RESULTS: Overall, among GT4-infected participants treated with 12 or 16 weeks of elbasvir/grazoprevir ± ribavirin, the SVR12 efficacy rates were 96.4% (107/111) in treatment-naïve participants and 88.6% (39/44) in treatment-experienced participants. The SVR12 rates were 96.0% (97/101) in treatment-naïve participants treated with 12 weeks of elbasvir/grazoprevir and 100% (8/8) in treatment-experienced participants treated with 16 weeks of elbasvir/grazoprevir plus ribavirin. Efficacy was not impacted by GT4 subtype. CONCLUSIONS: The regimens of 12 weeks of elbasvir/grazoprevir without ribavirin, and 16 weeks of elbasvir/grazoprevir plus ribavirin, were efficacious in HCV GT4-infected treatment-naïve and treatment-experienced participants respectively. Baseline NS5A resistance-associated substitutions did not impact the efficacy of elbasvir/grazoprevir in GT4-infected participants.
Authors: Mohamed Darwish Ahmed Abd Alla; Reham M Dawood; Hassan Abd El-Hafeth Rashed; Galal Farrag; Islam Abdelmawla Emran Ammar; Mohamed Mahmoud Abdel-Halim Mahmoud; Ghada M Salum; Ahmed Mohamed Abdulhamid Altanbouly; Mai A El Meguid; Mostafa K El Awady Journal: Arch Virol Date: 2021-02-03 Impact factor: 2.574
Authors: Mohammed A Babatin; Abdullah S AlGhamdi; Abdullah M Assiri; Haziz AlBiladi; Hammad S AlOthmani; Mohammed H Mogharbel; Wedad Mahallawi; Tarik Asselah; Faisal M Sanai Journal: Saudi J Gastroenterol Date: 2019 Jan-Feb Impact factor: 2.485
Authors: Reham M Dawood; Ahmed A Gomaa; Mai Abd El Meguid; Essam A Hassan; Ghada M Salum; Hany Mahmoud Fares; Mostafa K El Awady; Eman M Fares; Gamal Esmat Journal: Asian Pac J Cancer Prev Date: 2022-04-01
Authors: Ahmad AlEid; Areej Al Balkhi; Adel Qutub; Shahem Abbarh; Abed AlLehibi; Abdullah Almtawa; Nawwaf Al Otaibi; Ahmed AlGhamdi; Adel AlGhamdi; Abdulrahman Alamr; Shameem Ahmad; Khalid Al Sayari; Bashaar Al Ibrahim; Abdullah AlKhathlan Journal: Saudi J Gastroenterol Date: 2022 May-Jun Impact factor: 3.214